## **Core Concept**
Erlotinib is a type of targeted cancer therapy known as a **tyrosine kinase inhibitor**. It specifically targets the **epidermal growth factor receptor (EGFR)** tyrosine kinase. By inhibiting EGFR, erlotinib blocks the signal transduction events implicated in the proliferation and survival of cancer cells.

## **Why the Correct Answer is Right**
Erlotinib is primarily used in the treatment of **non-small cell lung cancer (NSCLC)** and **pancreatic cancer**. In NSCLC, it is particularly effective in patients with **specific EGFR mutations**. The drug works by competitively inhibiting the ATP binding site of EGFR tyrosine kinase, which prevents the phosphorylation and activation of downstream proteins that promote cell division and survival.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is blank and cannot be evaluated.
- **Option B:** This option is blank and cannot be evaluated.
- **Option D:** This option is blank and cannot be evaluated.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that erlotinib is most effective in NSCLC patients with **exon 19 deletions or exon 21 (L858R) mutations** in the EGFR gene. Patients with these mutations are more likely to respond to EGFR inhibitors like erlotinib.

## **Correct Answer:** C.